# Syntimmune, Inc.: Form D filings

Syntimmune, Inc., a biotechnology company in New York, NY, filed 2 Form D notices with the SEC between 2014 and 2017. The latest, on June 28, 2017, reports $18 million sold of a $50 million offering to 3 investors.

Find out what Syntimmune, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Syntimmune%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Syntimmune%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fsyntimmune-inc-1622964)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Syntimmune%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Syntimmune%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fsyntimmune-inc-1622964)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in New York](https://specstream.ai/data/form-d/state/new-york): 4,357 rows, by operating companies, filed since November 1, 2024, $123.57, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/new-york
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 257 PARK AVENUE SOUTH, 15TH FLOOR, New York, NY, 10010
- Phone: 212-498-0011 EXT 301
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Year incorporated: 2013
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1622964

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Jun 28, 2017 | New notice | $49,999,991 | $17,999,998 | $31,999,993 | 3 | Jun 19, 2017 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1622964/000162296417000001/0001622964-17-000001-index.htm) |
| Oct 24, 2014 | New notice | $26,000,002 | $8,000,001 | $18,000,001 | 5 | Oct 17, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1622964/000162296414000001/0001622964-14-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Seth Harrison, M.D. | Director |  |
| Richard Blumberg, M.D. | Director |  |
| David De Graaf, Ph.D. | Executive Officer, Director |  |
| Sam Hall, Ph.D. | Director |  |
| Burt Adelman, M.D. | Director |  |
| Aaron Kantoff | Director |  |
| Laurence Blumberg, M.D. | Executive Officer, Director |  |

## Other biotechnology companies in New York that filed recently

- [Swep Bio, Inc.](https://specstream.ai/data/form-d/company/swep-bio-inc-2159106) $2.5 million · Oct 29, 2026
- [Hypercell Technologies Inc.](https://specstream.ai/data/form-d/company/hypercell-technologies-inc-1882357) $3 million · Oct 14, 2026
- [CAD Therapeutics, Inc.](https://specstream.ai/data/form-d/company/cad-therapeutics-inc-2157566) $4 million · Oct 2, 2026
- [Vicora, Inc.](https://specstream.ai/data/form-d/company/vicora-inc-2091847) $2.3 million · Sep 18, 2026
- [GevRx Nutraceuticals, Inc.](https://specstream.ai/data/form-d/company/gevrx-nutraceuticals-inc-2156105) $300,000 · Sep 18, 2026
- [Episteme Prognostics, Inc.](https://specstream.ai/data/form-d/company/episteme-prognostics-inc-1902402) $5.1 million · Sep 4, 2026

[Every Form D from the week of Jun 26, 2017](https://specstream.ai/data/form-d/week/2017-06-26) · [All recent filings in New York](https://specstream.ai/data/form-d/state/new-york) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what Syntimmune, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).